Radstake, T R D J <br/><br/>
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.  [electronic resource] 

 -  Annals of the rheumatic diseases  Nov 2009 
 - 1739-45 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/ard.2008.092833  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Aged<br/>Antibodies, Anti-Idiotypic--biosynthesis<br/>Antibodies, Monoclonal--blood<br/>Antibodies, Monoclonal, Humanized<br/>Arthritis, Rheumatoid--blood<br/>Female<br/>Humans<br/>Infliximab<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Radioimmunoassay--methods<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors